Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers

    NEXT STORY
    Novavax Announces Facility Expansion to Support Global Vaccine Development
    PREV STORY
    Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

    Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases ...

    author_avatar
    NASDAQ Market News

    Translate Bio to Participate in Upcoming Investor Conferences

    author_avatar
    NASDAQ Market News

    Outlook into the Antimicrobial Susceptibility Test Global Market to 2027 – Impact of COVID-19

    author_avatar
    NASDAQ Market News